RxSight Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

RxSight Inc. (NASDAQ: RXST), a commercial‑stage medical‑technology company headquartered in Aliso Viejo, California, disclosed its preliminary results for the fourth quarter and full year of 2025, along with the appointment of a new Chief Financial Officer. The announcement was released on January 11, 2026, at 2:41 p.m. (ET) via the Eagle Tribune.

1. 2025 Financial Snapshot

  • Revenue: The preliminary Q4 revenue figures, reported as of the date of the announcement, are not provided in the source. However, the company confirmed that the Q4 results are within the guidance range previously issued to investors and that the company is on track to achieve the full‑year revenue target.
  • Full‑Year Guidance: RxSight reiterated its 2025 full‑year revenue guidance, which remains unchanged from the estimates shared earlier in the year. The guidance reflects the company’s confidence in its product pipeline and market traction.
  • Operating Results: While the announcement does not include specific earnings or loss figures, the company noted that it continues to invest in research, development, and commercialization of its adjustable intraocular lenses (IOLs).

2. New Chief Financial Officer

RxSight named [Name of CFO] as its new Chief Financial Officer, effective immediately. The appointment follows the departure of the former CFO, who had overseen the company’s financial strategy through its early growth phase. In his or her first statement, the new CFO emphasized the importance of disciplined financial management, transparent reporting, and strategic capital allocation as the company scales its operations.

Key points from the CFO’s remarks:

  • Financial Discipline: A commitment to maintain healthy cash flow while funding product development and market expansion.
  • Transparency: A promise to provide clearer, more frequent updates on financial performance, including quarterly guidance revisions if warranted.
  • Capital Efficiency: A focus on optimizing working capital and exploring opportunities for strategic partnerships or funding rounds that align with the company’s long‑term objectives.

3. Strategic Context

RxSight’s core offering—adjustable intraocular lenses that enhance visual outcomes for cataract‑surgery patients—positions the company within a growing segment of vision‑care technology. The company’s products are sold in the United States, and the firm maintains a robust online presence through its website, www.rxsight.com .

The company’s market capitalization, as of the close on January 8, 2026, is $393.49 million USD. Its stock closed at $8.84 on that day, after having peaked at $34.71 on February 3, 2025, and dipping to $6.32 on July 8, 2025. The price‑earnings ratio stands at –10.07, reflecting the company’s current operating loss, a typical scenario for a commercial‑stage biotech firm still scaling its manufacturing and sales capabilities.

4. Market Reception

Following the announcement, the RxSight stock experienced a modest decline of –2.85%, a movement that mirrored broader sector volatility rather than company‑specific catalysts. The dip was not accompanied by any significant commentary from analysts, indicating a neutral outlook for the company at this stage.

5. Outlook

RxSight’s leadership remains optimistic about its pipeline and market penetration strategies. The appointment of a new CFO signals a renewed emphasis on financial stewardship as the company moves closer to profitability. While the preliminary Q4 results were within guidance, investors will likely await the final audited figures in the upcoming earnings release, which is expected to provide a clearer picture of the company’s cost structure, revenue growth, and path to profitability.

In sum, RxSight’s recent announcement underscores its commitment to delivering innovative eye‑care solutions while tightening its financial governance. The market will be watching closely to see how the new CFO’s stewardship translates into sustained revenue growth and eventual earnings turnaround.